共 50 条
Hallmarks of neurodegenerative diseases
被引:583
|作者:
Wilson III, David M.
[1
]
Cookson, Mark R.
[2
]
Van Den Bosch, Ludo
[3
,4
]
Zetterberg, Henrik
[5
,6
,7
,8
,9
,10
]
Holtzman, David M.
[11
]
Dewachter, Ilse
[1
]
机构:
[1] Hasselt Univ, Biomed Res Inst, BIOMED, B-3500 Hasselt, Belgium
[2] Natl Inst Aging, Lab Neurogenet, NIH, Bethesda, MD 20892 USA
[3] Univ Leuven, Expt Neurol & Leuven Brain Inst LBI, Dept Neurosci, KU Leuven, B-3000 Leuven, Belgium
[4] Ctr Brain & Dis Res VIB, Lab Neurobiol, B-3000 Leuven, Belgium
[5] Sahlgrenska Acad Univ Gothenburg, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden
[6] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden
[7] UCL Inst Neurol, Dept Neurodegenerat Dis, Queen Sq, London, England
[8] UK Dementia Res Inst UCL, London, England
[9] Hong Kong Ctr Neurodegenerat Dis, Clear Water Bay, Hong Kong, Peoples R China
[10] UW, Dept Med, Sch Med & Publ Hlth, Madison, WI USA
[11] Washington Univ St Louis, Hope Ctr Neurol Disorders, Knight Alzheimers Dis Res Ctr, Dept Neurol, St Louis, MO USA
来源:
基金:
美国国家卫生研究院;
欧洲研究理事会;
瑞典研究理事会;
欧盟地平线“2020”;
关键词:
AMYOTROPHIC-LATERAL-SCLEROSIS;
UBIQUITIN-PROTEASOME SYSTEM;
MOTOR-NEURON DISEASE;
ALPHA-SYNUCLEIN TOXICITY;
FRONTOTEMPORAL DEMENTIA;
ALZHEIMERS-DISEASE;
DNA-DAMAGE;
PARKINSON-DISEASE;
OXIDATIVE STRESS;
AMYLOID-BETA;
D O I:
10.1016/j.cell.2022.12.032
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Decades of research have identified genetic factors and biochemical pathways involved in neurodegenera-tive diseases (NDDs). We present evidence for the following eight hallmarks of NDD: pathological protein ag-gregation, synaptic and neuronal network dysfunction, aberrant proteostasis, cytoskeletal abnormalities, altered energy homeostasis, DNA and RNA defects, inflammation, and neuronal cell death. We describe the hallmarks, their biomarkers, and their interactions as a framework to study NDDs using a holistic approach. The framework can serve as a basis for defining pathogenic mechanisms, categorizing different NDDs based on their primary hallmarks, stratifying patients within a specific NDD, and designing multi-tar-geted, personalized therapies to effectively halt NDDs.
引用
收藏
页码:693 / 714
页数:22
相关论文